Inflammation, infection and treatments during severe cystic fibrosis flare-ups

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

UNIFIED-CF recruits adults with confirmed cystic fibrosis at participating UK centres while they are clinically stable and follows them for up to two years to capture severe pulmonary exacerbations treated with intravenous antibiotics. When a qualifying exacerbation occurs, investigators record symptoms and lung function during recovery and collect blood, sputum and stool samples. The study is event-driven and aims to complete recruitment once 125 exacerbations have been captured, enrolling up to 300 participants across several UK sites and allowing reuse of baseline data from the CF-Tracker project where available. Collected clinical and biological data will be compared across different antibiotic regimens to explore mechanisms linked to treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Confirmed diagnosis of cystic fibrosis (CF), defined as presence of two pathogenic CF-causing CFTR mutations AND clinical features consistent with a diagnosis of CF, OR presence of at least one pathogenic CF-causing CFTR mutation AND sweat chloride (before use of CFTR modulators) \>60mmol/L AND clinical features consistent with a diagnosis of CF.
2. Receiving care from a UK Adult Cystic Fibrosis Centre taking part in the study.
3. EITHER:

   • Have had at least 1 previous exacerbation of CF lung disease, treated with intravenous antibiotics, in the previous 12 months.

   OR

   • Enrolled in the CF-Tracker study (IRAS ID 338539) within the last 24 months (dated from date of completion of baseline Tracker visit)
4. In case of treatment for an exacerbation, likely to be treated with a ß-lactam or an anti-pseudomonal penicillin, combined with tobramycin or colistin, per CF Trust and NICE guidelines for 1st-line CF therapies.
5. Able to produce sputum (spontaneous or induced) at baseline visit.
6. Able to understand the patient information sheet, willing to consent to study protocol.

Exclusion Criteria:

1. When attending for the baseline visit participants should be clinically stable at the time of the visit. This is defined as no acute change in their baseline symptoms or presence of new viral symptoms. They should not be on additional antibiotics or anti-viral therapies for any reason (above their usual medications), and should have completed any such additional therapies at least 4 weeks prior.
2. Extensive antibiotic allergies or intolerances that mean they could not be treated with standard CF antibiotic regimens, as outlined in section 5.6.
3. Subjects with infection with Mycobacteria tuberculosis
4. Subjects with active ABPA, defined as receiving treatment for ABPA currently or within the last 4 months, or those considered at risk of requiring treatment for ABPA in the next 12 months.
5. Subjects receiving long term oral steroids at an equivalent dose of 10mg or more per day of prednisolone.
6. Subjects receiving any other form of long term immune-suppressant therapy.
7. Subjects with non-tuberculous mycobacteria (NTM) infection who are undergoing active eradication therapy. Subjects with chronic NTM infection who are not on eradication therapy, and not expecting to start this within the next 12 months, are not excluded.
8. Any other condition, co-morbidity or other feature that, in the opinion of the investigator would render the subject unable to complete the protocol or unsuitable for inclusion.
9. Planning on participating in a clinical trial of a novel experimental investigational medical product in the next 12 months.

Where it's running

• Manchester Adult Cystic Fibrosis Centre
  Manchester, United Kingdom Recruiting
• Cardiff and Vale University Health Board
  Cardiff, United Kingdom Not yet recruiting
• Royal Devon and Exeter Hospital (Wonford)
  Exeter, United Kingdom Not yet recruiting
• Leeds Adult CF Centre
  Leeds, United Kingdom Not yet recruiting
• Liverpool Heart & Chest Hospital
  Liverpool, United Kingdom Not yet recruiting
• Newcastle Adult CF Centre
  Newcastle upon Tyne, United Kingdom Not yet recruiting

Study contacts

• Study coordinator: Alexander Horsley, MA MBChB MRCP PhD FERS
• Email: Alexander.horsley@manchester.ac.uk
• Phone: 01612915869

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Causes and risk factors of lung exacerbations in cystic fibrosis

  This project will test whether regular home and clinic sampling can identify causes and triggers of lung exacerbations in people with cystic fibrosis.

  Recruiting at 8 sites University of Manchester · Manchester, Manchester and 17 other locations · NCT06940531

• Oropharyngeal suction and physiotherapy to detect lung bacteria in kids with chronic lung disease

  A randomized study will test whether taking samples from the throat with suction, with or without prior physiotherapy, can reliably detect bacteria in children 5–18 with chronic lung disease, compared with standard sample methods.

  Recruiting Corporacion Parc Tauli · Sabadell, Barcelona · NCT07903792

• Seeing if CFTR functioncan be restored in CF through patient cells with rare mutations

  This study tests whether testing a patient’s own nasal cells in the lab can predict if CFTR-modulator therapies might help people with uncommon CF mutations.

  Recruiting at 3 sites Istituto Giannina Gaslini · Catania and 2 other locations · NCT07889973

• Perceptions and Intentions Around a Change in CF Treatment

  This study asks adults with cystic fibrosis currently on ETI whether they would switch to VTD if their doctor offered it and what factors influence that decision.

  Recruiting at 6 sites Fondation Ildys · Caen and 11 other locations · NCT07885410

• How the CF medicines elexacaftor, tezacaftor, and ivacaftor behave in the body

  This study tests how the CF medicines elexacaftor, tezacaftor, and ivacaftor move through the body in patients with cystic fibrosis who are already taking the combination therapy.

  Recruiting Phase 4 Istituto Giannina Gaslini · Genova · NCT07809867

• Autogenic Drainage vs. Mechanical Chest Percussion in Children with Cystic Fibrosis

  In children aged 6-12 with cystic fibrosis, this study tests whether autogenic drainage helps lung function and comfort more than mechanical percussion.

  Recruiting Riphah International University · Multan Khurd, Punjab Province · NCT07729787

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.